The demand for oncology biosimilar drugs has augmented in recent years. This is attributed to the rising prevalence of various types of cancers across the world. In addition, existing anti-cancer drugs in the pipeline are quite expensive, thus rendering them unaffordable to people in lower and middle income countries. As a consequence, the market for biosimilars has burgeoned.
For detailed insights on enhancing your product footprint, request for a sample here – https://www.factmr.com/connectus/sample?flag=S&rep_id=4800
However, the current COVID-19 pandemic is poised to stall growth trajectory of the market, owing to supply chain disruptions from leading biosimilar manufacturing hubs and shifting priorities of healthcare providers. These shifting priorities are delaying clinical trials for biosimilars, thus delaying their adoption. However, long-term prospects are highly optimistic, with the industry registering an aggrandizing CAGR of 29.4% by 2025-end.
Key Takeaways of Oncology Biosimilars Market Study:
- By drug class, the granulocyte-colony stimulating factor (G-CSF) category shall dominate the oncology biosimilars market, capturing more than 3/5th of the total market share. Rising adoption of chemotherapy is the key growth driver of the segment. However, monoclonal antibodies are set to grow the fastest, expanding 4.0x, attributed to modification of manufacturing facilities to develop complex and effective drugs.
For critical insights on this market, request for methodology here – https://www.factmr.com/connectus/sample?flag=RM&rep_id=4800
- By disease indication, the blood cancer and neutropenia segments are set to account for the majority of the market share, accounting for 22.3% and 54.7% respectively. Rising FDA approvals for biosimilar products manufactured by leading market players are attributed as key drivers behind the expansion. Examples of such drugs are filgrastim-sndz and filgrastim-aafi.
- By end-user, hospital pharmacies shall expand the fastest, at a whopping CAGR of 29.5%. The growing trend of physicians prescribing biosimilars instead of generic drugs is anticipated to heighten market prospects for the segment. More than half of the global oncology biosimilars market is set to be captured by the hospitals segment.
- Asia-Pacific dominates the oncology biosimilars market. Financial leverage by virtue of collaborations between leading giants is a key growth driver. The region is anticipated to capture over one-third market share, expanding at a CAGR of 30.7% across the forecast period. Trailing behind is North America, with a projected market share of 28.4% and a CAGR of 32.0%. New pipeline drugs are attributed as key growth levers.
For in-depth competitive analysis, buy now – https://www.factmr.com/checkout/4800/S
Global Oncology biosimilars Market Segmentation
Fact.MR has studied the global oncology biosimilars market with detailed segmentation on the basis of drug class, disease indication, distribution channel and region.
|G-CSF||Breast Cancer||Hospital Pharmacy||North America|
|Monoclonal Antibody||Non-Small Cell Lung Cancer||Retail Pharmacy||Europe|
|Hematopoietic Agents||Colorectal Cancer||Online Pharmacy||Asia Pacific|
|Neutropenia||Rest of the World|
Chronic Lymphocytic Leukemia (CLL)
For comprehensive insights on this market adoption, ask an analyst here – https://www.factmr.com/connectus/sample?flag=AE&rep_id=4800
Global Oncology Biosimilars Market: Competition Structure:
The global oncology biosimilars market consists of the following market players: Celltrion, Inc., Dr. Reddy’s Laboratories Ltd., Biocon, Teva Pharmaceutical Industries Ltd., and Sandoz International GmBh. This makes it a highly consolidated market. Collectively, these market players account for more than 70% of the market share. In order to increase their market footprints, these companies rely heavily on strengthening their product distribution networks through active collaborations.
Biocon, for instance, announced an exclusive global collaboration with Sandoz on next-generation biosimilars in 2018. Likewise, Dr. Reddy’s collaborated with TR Pharm to launch three biosimilars in Turkey in 2016. Other prominent market players in the global oncology biosimilars market include Pfizer, Inc., Celltrion, Inc., Sandoz International GmBh, STADA Arzneimittel AG and Apotex, Inc. to name a few.
Explore Fact.MR’s Comprehensive Coverage on Healthcare Landscape
Medical Grade Silicone Market Forecast, Trend, Analysis & Competition Tracking – Global Market Insights 2020 to 2030: https://www.factmr.com/report/5439/medical-grade-silicone-market
Diabetes Diagnostics Market Forecast, Trend, Analysis & Competition Tracking – Global Market Insights 2020 to 2030: https://www.factmr.com/report/5446/diabetes-diagnostics-market
Dermatology Diagnostic Devices Market Forecast, Trend, Analysis & Competition Tracking – Global Market Insights 2020 to 2030: https://www.factmr.com/report/5453/dermatology-diagnostic-devices-market
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.
US Sales Office:
11140 Rockville Pike
Rockville, MD 20852
Tel: +1 (628) 251-1583